Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity

@inproceedings{Seya2015AdjuvantFV,
  title={Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity},
  author={Tsukasa Seya and Hiroaki Shime and Yohei Takeda and Megumi Tatematsu and Ken Takashima and Misako Matsumoto},
  booktitle={Cancer science},
  year={2015}
}
Immune-enhancing adjuvants usually targets antigen (Ag)-presenting cells to tune up cellular and humoral immunity. CD141(+) dendritic cells (DC) represent the professional Ag-presenting cells in humans. In response to microbial pattern molecules, these DCs upgrade the maturation stage sufficient to improve cross-presentation of exogenous Ag, and… CONTINUE READING